Compass Therapeutics (CMPX) Share-based Compensation (2019 - 2026)

Compass Therapeutics (CMPX) has 7 years of Share-based Compensation data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 722.45% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (up 303.13% YoY), and the FY2025 full-year result was $13.7 million, down 24.31% from the prior year.
• Share-based Compensation eased to $5.1 million in Q1 2026, from $7.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $19.5 million in Q2 2025 to a low of -$4.4 million in Q4 2023.
• A 5-year average of $4.0 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation tumbled 525.46% in 2023 and jumped 722.45% in 2026, its largest moves.
• Tracing CMPX's Share-based Compensation over 5 years: stood at $1.0 million in 2022, then plunged by 525.46% to -$4.4 million in 2023, then surged by 151.32% to $2.2 million in 2024, then surged by 237.49% to $7.6 million in 2025, then tumbled by 32.83% to $5.1 million in 2026.
• Business Quant data shows CMPX's Share-based Compensation at $5.1 million in Q1 2026, $7.6 million in Q4 2025, and $2.2 million in Q3 2025.